Key result
Pharmacotherapy for calcific aortic valve disease, including statins, renin-angiotensin inhibitors, and anti-osteoporosis drugs, is reviewed as a strategy to prevent or slow disease progression.
Why the study?
Does pharmacotherapy prevent or slow down the progression of calcific aortic valve disease?
Does pharmacotherapy prevent or slow down the progression of calcific aortic valve disease?
This review summarizes the current research progress on pharmacotherapy for preventing or slowing the progression of calcific aortic valve disease.
Review highlights potential pharmacotherapy targets for calcific aortic valve disease; leaves open clinical efficacy pending prospective trials.
With the population aging and declining incidence of rheumatic heart disease, calcific aortic valve disease (CAVD) has become the most frequent valve disease and the common cause of aortic valve replacement. Patients with CAVD need to cope with a deteriorating quality of life and valve replacement is the only effective clinical option for the patients. Therefore, early pharmacotherapy is of great significance in prevention or slow-down of the progression of CAVD. For years CAVD was considered to be a passive wear and tear process of valves, but now it is recognized as an active and multi-factorial process. Histopathologic studies have revealed that inflammation, disorder of calcium and phosphorus metabolism and dyslipidemia are involved in the process of CAVD. Clinical trials of CAVD pharmacotherapy have been carried out based on those histopathologic studies. Statin, renin-angiotensin inhibitors and anti-osteoporosis drug are well studied in recent years. This article reviews the recent research progress of the pharmacotherapy for CAVD.
No takes yet. Share an insight, caveat, or question.
Du et al. (2016) conducted a review in Calcific aortic valve disease. Pharmacotherapy (statins, renin-angiotensin inhibitors, anti-osteoporosis drugs) was evaluated. Pharmacotherapy for calcific aortic valve disease, including statins, renin-angiotensin inhibitors, and anti-osteoporosis drugs, is reviewed as a strategy to prevent or slow disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: